BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7917941)

  • 1. Mitotane in adrenocortical carcinoma.
    Vassilopoulou-Sellin R; Guinee VF
    Br J Cancer; 1994 Oct; 70(4):779. PubMed ID: 7917941
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
    Schteingart DE
    N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
    J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging drugs for adrenocortical carcinoma.
    Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
    J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
    Baszko-Błaszyk D; Ochmańska K; Waśko R; Sowiński J
    Endokrynol Pol; 2011; 62(2):186-8. PubMed ID: 21528483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant mitotane in adrenocortical carcinoma.
    Machens A; Dralle H
    N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
    Szkodziak PR; Czuczwar P; Woźniak S; Szkodziak F; Paszkowski T
    Ginekol Pol; 2017; 88(10):576-577. PubMed ID: 29192420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
    Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
    Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mitotane in the treatment of adrenal carcinoma].
    Sane T
    Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later.
    Kasperlik-Załuska AA; Migdalska BM; Makowska AM
    Cancer; 1996 Oct; 78(7):1520-1. PubMed ID: 8839564
    [No Abstract]   [Full Text] [Related]  

  • 16. Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
    Kenney L; Hughes M
    Surg Oncol Clin N Am; 2023 Apr; 32(2):279-287. PubMed ID: 36925185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Lecka A; Ginalska-Malinowska M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discussion.
    J Am Coll Surg; 2016 Apr; 222(4):490-2. PubMed ID: 27016977
    [No Abstract]   [Full Text] [Related]  

  • 19. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive treatment of adrenocortical carcinoma.
    Terzolo M; Berruti A
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.